Chapter 27

• Symptoms and signs of heart failure with preserved left ventricular ejection fraction (LVEF > 50%).
• Presence of an underlying cause of heart failure with preserved ejection fraction (eg, comorbidities such as hypertension, coronary artery disease, diabetes, chronic kidney disease; or underlying valvular heart disease, restrictive cardiomyopathy, or specific myocardial diseases such as amyloidosis).
• Objective evidence of elevated left ventricular filling pressure (at rest or with exercise) on echocardiography or cardiac catheterization.

Heart failure with preserved ejection fraction (HFpEF) is an increasingly common, debilitating syndrome of the elderly, and one that carries a high rate of morbidity and mortality. HFpEF accounts for > 50% of all hospitalizations for heart failure, and while a recent patient-level meta-analysis found that patients with heart failure and reduced ejection fraction (HFrEF) have a worse prognosis compared to HFpEF, two earlier large epidemiologic studies found that patients with HFpEF have a mortality rate that is nearly identical to HFrEF. Regardless of underlying ejection fraction, survival for all heart failure (HF) patients is poor, especially after HF hospitalization.

HFpEF is the preferred term for patients with a normal ejection fraction who have the syndrome of HF, because HFpEF highlights the fact that HF is a syndrome and not a distinct clinical or pathophysiologic entity. Many investigators and experts have used the term “diastolic heart failure” for HFpEF in the past. However, this term is not ideal for two main reasons. First, there is ample evidence that patients with HFpEF have abnormalities in systolic function (as defined by tissue Doppler imaging) despite a normal ejection fraction, and many patients with HFrEF have abnormal diastolic function. Second, in the clinical setting, patients with HF are currently classified into two categories: low ejection fraction (< 50%) and preserved ejection fraction (> 50%). By calling HFpEF “diastolic HF,” clinicians may not consider the entire differential diagnosis of HFpEF (of which pure diastolic dysfunction is only one cause). HFpEF has also previously been called “HF with preserved systolic function” or “HF with normal systolic function.” As stated earlier, it is now clear that many patients with HFpEF have abnormalities in systolic function; therefore, HFpEF is a better term.

Finally, HFpEF has the advantage of being an easy mnemonic for patients to remember. HFpEF sounds like “HUFF-PUFF,” which helps patients understand this syndrome, in which dyspnea and fatigue are two of the most common symptoms.

Borlaug BA, et al. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32(6):670–9.   [PubMed: 21138935]
Maeder MT, et al. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2009;53(11):905–18.   [PubMed: 19281919]
Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012;33(14):1750–7.   [PubMed: 21821849]

Since HFpEF is heterogeneous, there is no single mechanism that can explain the pathophysiology of ...

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

Subscription Options

AccessCardiology Full Site: One-Year Subscription

Connect to the full suite of AccessCardiology content and resources including textbooks such as Hurst's the Heart and Cardiology Clinical Questions, a unique library of multimedia, including heart imaging, an integrated drug database, and more.